BelHealth Investment Partners has named Rebecca Yu as a senior associate. Previously, Yu worked at Warburg Pincus where she served as a vice president in the healthcare and consumer group.
New York, New York – July 24, 2017 – BelHealth Investment Partners (“BelHealth”), a healthcare-focused private equity firm, announced that Rebecca Yu has joined the team as a Senior Associate. Ms. Yu’s responsibilities will range from deal origination and structuring to due diligence, execution and portfolio company monitoring.
Before joining BelHealth, Ms. Yu worked as a Vice President in the Healthcare and Consumer Group at Warburg Pincus, where she focused on sourcing, analyzing and executing growth equity and buyout opportunities in the upper middle market. She focused her efforts on several healthcare sub-sectors that are currently of high interest to BelHealth. Her other work experience includes two years at Goldman Sachs as a Securities Analyst. Ms. Yu obtained a Master of Business Administration from Stanford Graduate School of Business where she was an Arjay Miller Scholar and a Bachelor of Arts in Physics, Magna Cum Laude, from Princeton University.
Harold S. Blue, Managing Partner of BelHealth, said, “We are thrilled to have Rebecca join BelHealth and she is a perfect addition to our growing team. She will bring valuable experience with a fresh perspective and has an excellent pedigree after working for two top firms in the financial services world. She will work with the senior team on origination of new deals and also brings an outstanding technical skill set which will be very useful for analysis of new opportunities.”
About BelHealth Investment Partners
BelHealth Investment Partners, based in New York, New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management, and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm typically invests $20-50 million per platform company across three core healthcare segments: Services, Products, and Distribution. BelHealth is currently investing from Fund II, a $350 million fund.
For further information, please visit: BelHealth Investment Partners: www.belhealth.com